
    
      Enrolled subjects continued to receive the same dose strength of Medisorb naltrexone (ie, 190
      mg or 380 mg) they had received in Study ALK21-003-EXT (NCT01218971). Assigned dose strength
      (high or low) was not revealed to the subject, the study investigators, or any blinded member
      of the clinical study team for the duration of the study period. Placebo was not
      administered.
    
  